<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04743453</url>
  </required_header>
  <id_info>
    <org_study_id>41012620.6.1001.0068</org_study_id>
    <nct_id>NCT04743453</nct_id>
  </id_info>
  <brief_title>EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS.</brief_title>
  <official_title>EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS: A Prospective, Randomized, Single-blinded, Placebo- Controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce plasma glucose and haemoglobin&#xD;
      A1c(HbA1c) in patients with type 2 diabetes mellitus by increasing urinary glucose excretion&#xD;
      in a non-insulin-dependent fashion.&#xD;
&#xD;
      However, in some situations lead to a diminished number of functional glomeruli with a&#xD;
      consequent hyperfiltration in the remaining ones. This fact may be where the use of SGLT2&#xD;
      inhibitor could attenuate the renal damage.&#xD;
&#xD;
      The purpose of our study is to evaluate the impact of using dapagliflozin on the renal&#xD;
      functional deterioration of renal transplanted patients diabetics or not.&#xD;
&#xD;
      This is a prospective, randomized, single-blinded, double-center, controlled trial.&#xD;
&#xD;
      Patients will be randomized to add either Dapagliflozin 10 mg or Placebo to their treatment.&#xD;
      Study drug will be administered by once-daily orallly. The first dose MUST be started within&#xD;
      1 and 7 days after randomization. The subsequent doses will be administered 24 ± 4 hours&#xD;
      after the previous dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 30, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized to add either Dapagliflozin 10 mg or Placebo to their treatment. Study drug will be administered by once-daily orallly.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the mean ΔmGFR, between baseline and one year after randomization.</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the mean ΔmGFR, between baseline and one year after randomization between groups: Dapaglifozin and Placebo groups. (ΔmGFR is defind as the difference between measured GFR (mGFR) at baseline and at one year).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Kidney Transplantation</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Diabetes Complications</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Dapagliflozin 10 mg: Study drug will be administered by once-daily orallly. The first dose MUST be started within 1 and 7 days after randomization. The subsequent doses will be administered 24 ± 4 hours after the previous dose.</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered by once-daily orallly. The first dose MUST be started within 1 and 7 days after randomization. The subsequent doses will be administered 24 ± 4 hours after the previous dose.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Renal Transplanted patients with one to 5 years after transplantation, being followed&#xD;
             at the out-patient clinics of the HCFMUSP and HRim;&#xD;
&#xD;
          2. ≥18years of age;&#xD;
&#xD;
          3. 45 ≥ eGFR ≥ 25 mL/min/1.73m2 or 45&lt;eGFR&lt;60 ml/min/1.73m2 with a loss of eGFR of ≥10%&#xD;
             in the last year.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Type 1 diabetes;&#xD;
&#xD;
          2. New York Heart Association Class IV congestive heart failure;&#xD;
&#xD;
          3. Myocardial infarction, unstable angina, stroke or transient ischaemic attack within 8&#xD;
             weeks prior to enrolment;&#xD;
&#xD;
          4. Coronary revascularization (percutaneous coronary intervention or coronary artery&#xD;
             bypass grafting) or valvular repair/replacement within 8weeks prior to enrolment;&#xD;
&#xD;
          5. Any condition outside the renal and cardiovascular study area with a life expectancy&#xD;
             of &lt; 1 year based on investigator's clinical judgement;&#xD;
&#xD;
          6. Hepatic impairment [aspartate transaminase or alanine transaminase &gt;3 times the upper&#xD;
             limit of normal (ULN) or total bilirubin &gt;2 times the ULN at the time of enrolment;&#xD;
&#xD;
          7. Acute or chronic antibody mediated rejection;&#xD;
&#xD;
          8. Albuminuria due to other causes (mTOR inhibitors, Polyoma nephropathy,&#xD;
             lymphoproliferative disorder etc…)&#xD;
&#xD;
          9. Patients with a previous medical history of recurrent urinary tract infections or&#xD;
             severe genital infection;&#xD;
&#xD;
         10. Renal biopsies showing acute or chronic anti-body mediated rejection, transplant&#xD;
             glomerulopathy, BKV nephropathy.&#xD;
&#xD;
         11. Patients under any other IS regimen besides Tacrolimus/MPA/Steroids&#xD;
&#xD;
         12. Pregnant patients as well as those breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elias David-Neto, MD,PhD</last_name>
    <phone>55-11-2661-8089</phone>
    <email>pesquisaclinicautr.ichc@hc.fm.usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fabiana Agena, MS, PhD</last_name>
    <phone>55-11-2661-8089</phone>
    <email>fabiana.agena@hc.fm.usp.br</email>
  </overall_contact_backup>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 2, 2021</study_first_submitted>
  <study_first_submitted_qc>February 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2021</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney Transplantation</keyword>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

